• Search Research Projects
  • Search Researchers
  • How to Use
  1. Back to previous page

Reliability of immuno deficient mice as a tool for preclinical antitumor drug evaluation

Research Project

Project/Area Number 07680925
Research Category

Grant-in-Aid for Scientific Research (C)

Allocation TypeSingle-year Grants
Section一般
Research Field Laboratory animal science
Research InstitutionCentral Institute for Experimental Animals

Principal Investigator

YOSHIMURA Masumi  Cent.inst.Expr.Anim. Laboratory of Oncolygy Researcher, 腫瘍研究室, 研究員 (40150867)

Co-Investigator(Kenkyū-buntansha) ENDO Sachio  Cent.Inst.Expr.Anim. Animal Resource Center Researcher, 飼育技術研究室, 研究員 (50203667)
OHNISHI Yasuyuki  Cent.Inst.expr.Anim. Laboratory of Oncology Researcher, 腫瘍研究室, 研究員 (70201382)
Project Period (FY) 1995 – 1996
Project Status Completed (Fiscal Year 1998)
Budget Amount *help
¥800,000 (Direct Cost: ¥800,000)
Fiscal Year 1996: ¥800,000 (Direct Cost: ¥800,000)
KeywordsHuman Tumor / Immunodeficient Mouse / Nude Mouse / SCID Mouse / RAG-2ko Mouse / Cancer Xenograft / Anticancer Drug / Chemosensitivity / 担癌動物 / 薬効評価システム
Research Abstract

Immune deficient mice are useful as host of human tumor xenografts (HTXS), especially nude mouse has been widely used in evaluation of new antitumor drugs. We and many others have shown that the nude mouse/IITX model has possessed closed clinical reproducibility as an antitumor drug evaluation system. The SCID mouse (scid/scid) is a potential new recipient of HTX, and it has been reported that the mouse has advantages in the establishment of certain types of human tumor when compared with the nude mouse. In addition, recent gene engineering technology has led to mice with similar phenotype, but different mechanisms, to SCID mouse such as the recombination activating gene-2 (RAG-2) knockout mouse. In this study, we compared toxicity of mice to antitumor agents and sensitivities of HTXs in SCID mice with those in nude mice in order to validate the use of the SCID mouse in this field.
In toxicity study, SCID mouse showed rather hyper toxic sensitivities to topoisomerase II inhibitors and DNA intercalaters although RAG-2 knockout mouse showed no different sensitivities.
Sensitivities to antitumor drugs of HTXs implanted in C.B-17-scid and in BALB/cA-nu were compared. In a total of 2,5 pairs of corresponding experiments with each host mouse strain (5 HTXS x 5 drug treatment groups), we obtained consistent results in 23 (92.0%) experiments consisting of 10 which were both significantly effective and 13 which were both ineffective, although the remainir2g two (8.0%) experiments showed inconsistent results. A human T-cell lymphoma cell line, LM-2-JCK, implanted in nude mice, was resistant to treatment with 65 mg/kg of cyclaphasphamide. However, this tumor showed sensitive to the same treatment when implanted in either SCID mice or mice with a recombination activating gene-2 defect [BALB/cA-TgH(RAG-2)], suggesting that the genetic immune background of the host mouse should not be overlooked as a factor affecting tumors.

Report

(3 results)
  • 1998 Final Research Report Summary
  • 1996 Annual Research Report
  • 1995 Annual Research Report
  • Research Products

    (28 results)

All Other

All Publications (28 results)

  • [Publications] 吉村マスミ: "Chemotherapeutic profiles of human tumors implanted in SCIDmise showing appreciable inconsistencies with those in nude mice"Exp. Anim. 46. 153-156 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 吉村マスミ: "Quarantine for contaminated pathogens in transplantable human tumor or infecition in bearing mice"Exp. Anim. 46. 161-164 (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 大西保行: "Practical role of genetic profiling and preservation stock of human tumor xenograf tlines as a tool in animal experiments for antitumor drug evaluation"Lab. Anim. in press (1997)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 大西保行: "Lactic dehydrogenase virus(LDHV) contamination in human tumor xenografts and its elimination"J. Natl. Cancer Inst. 87. 538-539 (1995)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 大西保行: "Prolonged suruvival of mice with human grastic cancer treated with an aniti-c-erbB-2 monoclonal antlbody"Br. J. Cancer. 71. 969-973 (1995)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 阿部良行: "P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cell in vivo"Br. J. Cancer. 74. 1929-1934 (1996)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 徳田裕: "In vitro and in vivo anti-tumor effects of a humanized monoclonal antibody aIgainst c-erbB-2 product"Br. J. Cancer. 73. 1362-1365 (1996)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 稲葉實: "Conbination therapy of doxifluridine, pirarubicin and cisplatin for human gastric cancer implanted in nude mice"癌と化学療法. 22. 1793-1798 (1995)

    • Description
      「研究成果報告書概要(和文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yoshimura, M.: "Chemotherapeutic profiles of human tumors implanted in SCIDmise showing appreciable inconsistencies with those in nude mice"Exp. Anim.. 46. 153-156 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Yoshimura, M.: "Quarantine for contaminated pathogens in transplantable human tumor or infections in bearing mice"Exp. Anim.. 46. 161-164 (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Ohnishi, Y.: "Practical role of genetic profiling and preservation stock of human tumor xenograf tlines as a tool in animal experiments for antitumor drug evaluation"Lab. Anim. (in press). (1997)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Ohnishi, Y.: "Lactic dehydrogenase virus (LDHV) contamination in human tumor xenografts and its elimination"J. Natl. Cancer Inst.. 87. 538-539 (1995)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Ohnishi, Y.: "Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antlbody"Br.J.Cancer. 71. 969-973 (1995)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Abe, Y.: "P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cell in vivo"Br.J.Cancer. 74. 1929-1934 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Tokuda, Y.: "In vitro and in vivo anti-tumor effects of a humannized monoclonal antibody aigainst c-erbB-2 product"Br.J.Cancer. 73. 1362-1365 (1996)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] Inaba, M.: "Conbination therapy of doxifluridine, Pirarubicin and cisplatin for human gastric cancer implanted in nude mice"Jpn.J.Cancer Chemother.. 22. 1793-1798 (1995)

    • Description
      「研究成果報告書概要(欧文)」より
    • Related Report
      1998 Final Research Report Summary
  • [Publications] 吉村マスミ: "Chemotherapeutic profiles of human tumors implanted in SCIDmise showing appreciable inconsistencies with those in nude mice" Exp.Anim. 46・2. in press (1997)

    • Related Report
      1996 Annual Research Report
  • [Publications] 吉村マスミ: "Quarantine for contaminated pathogens in transplantable human tumor or infections in bearing mice" Exp.Anim. 46・2. in press (1997)

    • Related Report
      1996 Annual Research Report
  • [Publications] 大西保行: "Practical role of genetic profiling and preservation stock of human tumor xenograf tlines as a tool in animal experiments for antitumor drug evaluation." Lab.Anim. in press (1997)

    • Related Report
      1996 Annual Research Report
  • [Publications] 大西保行: "Lactic dehydrogenase virus (LDHV) contamination in human tumor xenografts and its elimination" J.Natl.Cancer Inst. 87. 538-539 (1995)

    • Related Report
      1996 Annual Research Report
  • [Publications] 大西保行: "Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antibody." Br.J.Cancer. 71. 969-973 (1995)

    • Related Report
      1996 Annual Research Report
  • [Publications] 阿部良行: "P-glycoprotein-mediated acquired multidrug resistance of human lung cancer cell in vivo." Br.J.Cancer. 74. 1929-1934 (1996)

    • Related Report
      1996 Annual Research Report
  • [Publications] 徳田裕: "In vitro and in vivo anti-tumor effects of a humanized monoclonal antibody aIgainst c-erbB-2 product" Br.J.Cancer. 73. 1362-1365 (1996)

    • Related Report
      1996 Annual Research Report
  • [Publications] 稲葉實: "Conbination therapy of doxifluridine,pirarubicin and cisplatin for human gastric cancer implanted in nude mice." 癌と化学療法. 22. 1793-1798 (1995)

    • Related Report
      1996 Annual Research Report
  • [Publications] 徳田 裕: "In vitro and in vivo anti-tumor effects of a humanized monoclonal antibody against c-erbB-2 product." Br.J.Cancer. (in press). (1996)

    • Related Report
      1995 Annual Research Report
  • [Publications] 大西保行: "Prolonged survival of mice with human gastric cancer treated with an anti-c-erbB-2 monoclonal antlbody." Br.J.Cancer. 71. 969-973 (1995)

    • Related Report
      1995 Annual Research Report
  • [Publications] 大西保行: "Lactic dehydrogenase virus(LDHV)contamination in human tumor xenografts and its elimination." J.Natl.Cancer Inst.87. 538-839 (1995)

    • Related Report
      1995 Annual Research Report
  • [Publications] 稲葉實: "ヌードマウス移植ヒト胃癌に対するDoxifluridine,PirarubicinおよびCisplatinの3剤併用療法。" 癌と化学療法. 22. 1793-1798 (1995)

    • Related Report
      1995 Annual Research Report

URL: 

Published: 1996-04-01   Modified: 2016-04-21  

Information User Guide FAQ News Terms of Use Attribution of KAKENHI

Powered by NII kakenhi